Capital expenditure · 2011–2025
Iovance Biotherapeutics capital expenditure
$33.8M+205.7% · FY2025
Iovance Biotherapeutics (IOVA) reported $33.8M in capital expenditure for fiscal 2025, +205.7% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $33.8M | +205.7% | Open → |
| FY20242024-12-31 | $11.1M | −50.3% | Open → |
| FY20232023-12-31 | $22.3M | +9.1% | Open → |
| FY20222022-12-31 | $20.4M | −45.6% | Open → |
| FY20212021-12-31 | $37.6M | −19.7% | Open → |
| FY20202020-12-31 | $46.8M | +576.5% | Open → |
| FY20192019-12-31 | $6.9M | +477.4% | Open → |
| FY20182018-12-31 | $1.2M | +16.5% | Open → |
| FY20172017-12-31 | $1.0M | −32.4% | Open → |
| FY20162016-12-31 | $1.5M | +33.1% | Open → |
| FY20152015-12-31 | $1.1M | −28.2% | Open → |
| FY20142014-12-31 | $1.6M | +12,146.2% | Open → |
| FY20132013-12-31 | $13,000 | +$13,000 | Open → |
| FY20122012-12-31 | $0 | −100.0% | Open → |
| FY20112011-12-31 | $31,053 | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +64.8%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Iovance Biotherapeutics capital expenditure |url=https://companiesranked.com/en/company/iovance-biotherapeutics/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Iovance Biotherapeutics capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/iovance-biotherapeutics/capital-expenditureBibTeX
@misc{companiesranked-en-company-iovance-biotherapeutics-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Iovance Biotherapeutics capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/iovance-biotherapeutics/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-018899 · February 24, 2026
{{cite web |title=Iovance Biotherapeutics capital expenditure — 10-K (0001104659-26-018899) |url=https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.